Stock EVT EVOTEC SE
Add to a list
To use this feature you must be a member
Log inSign up

Financials Evotec SE

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Market Closed - Xetra
Other stock markets
 11:35:04 2024-05-31 am EDT 		5-day change 1st Jan Change
8.655 EUR +3.04% Intraday chart for Evotec SE -2.15% -59.33%
May. 30 Evotec Partners With French Institutions, Company to Research Obesity MT
May. 30 Evotec Joins Collaboration to Identify New Therapies for Obesity, Metabolic Diseases MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 3,473 4,950 7,444 2,696 3,765 1,534 - -
Enterprise Value (EV) 1 3,614 4,949 7,099 2,485 3,765 1,803 1,769 1,605
P/E ratio 92.2 x 757 x 32.7 x -15.4 x -45.3 x -58.3 x 32.3 x 25.7 x
Yield - - - - - - - -
Capitalization / Revenue 7.78 x 9.88 x 12 x 3.59 x 4.82 x 1.74 x 1.48 x 1.32 x
EV / Revenue 8.1 x 9.88 x 11.5 x 3.31 x 4.82 x 2.05 x 1.71 x 1.38 x
EV / EBITDA 29.3 x 46.4 x 66.2 x 24.4 x 56.7 x 18.5 x 9.31 x 6.65 x
EV / FCF 332 x -91.1 x 2,155 x 114 x - -8.8 x 26.4 x 15 x
FCF Yield 0.3% -1.1% 0.05% 0.88% - -11.4% 3.79% 6.66%
Price to Book 7.25 x 6.86 x 5.44 x 2.27 x - 1.43 x 1.36 x 1.33 x
Nbr of stocks (in thousands) 150,653 163,476 175,162 176,703 176,936 177,292 - -
Reference price 2 23.05 30.28 42.50 15.26 21.28 8.655 8.655 8.655
Announcement Date 3/26/20 3/25/21 4/12/22 5/12/23 4/24/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 446.4 500.9 618 751.4 781.4 881.4 1,037 1,160
EBITDA 1 123.1 106.6 107.3 101.7 66.35 97.26 190.1 241.3
EBIT 1 62.59 48.52 41 20.85 -26.63 -9.858 68.17 110.9
Operating Margin 14.02% 9.69% 6.63% 2.77% -3.41% -1.12% 6.58% 9.57%
Earnings before Tax (EBT) 1 56.56 25.81 237 -154 -80.59 -32.18 39.42 98.73
Net income 1 38.07 6.252 215.5 -175.7 -83.91 -27.89 32.32 76.84
Net margin 8.53% 1.25% 34.87% -23.38% -10.74% -3.16% 3.12% 6.63%
EPS 2 0.2500 0.0400 1.300 -0.9900 -0.4700 -0.1484 0.2683 0.3372
Free Cash Flow 1 10.89 -54.35 3.294 21.75 - -205 67 107
FCF margin 2.44% -10.85% 0.53% 2.89% - -23.26% 6.46% 9.23%
FCF Conversion (EBITDA) 8.85% - 3.07% 21.4% - - 35.24% 44.34%
FCF Conversion (Net income) 28.61% - 1.53% - - - 207.33% 139.26%
Dividend per Share 2 - - - - - - - -
Announcement Date 3/26/20 3/25/21 4/12/22 5/12/23 4/24/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 Q4 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 231 187.1 164.7 172.2 336.9 173.9 240.7 170.3 383.8 196.3 250.1 208.7 207.6 229.9 250.7 245.5 245.8
EBITDA 1 47.27 37.21 18.9 14.7 33.64 10.96 57.05 - 26.1 24.11 16.14 7.815 19.73 27.37 36.09 - -
EBIT 1 18.92 14.94 0.463 -3.77 -3.307 -13.53 37.69 -36.29 - -12.19 -7.687 -14.74 -4.233 2.116 10.18 - -
Operating Margin 8.19% 7.99% 0.28% -2.19% -0.98% -7.78% 15.66% -21.31% - -6.21% -3.07% -7.06% -2.04% 0.92% 4.06% - -
Earnings before Tax (EBT) 1 - -17.84 - -24.34 - -43.36 -17.52 -20.44 - -29.92 -24.02 -26.78 -2.761 5.756 13.64 - -
Net income 1 - -31.48 -73.24 -27.94 -101.2 -47.28 -27.2 -14.93 -28.83 -38.96 -16.13 -20.67 -11.7 -1.051 2.121 - -
Net margin - -16.83% -44.48% -16.22% -30.03% -27.19% -11.3% -8.77% -7.51% -19.85% -6.45% -9.9% -5.63% -0.46% 0.85% - -
EPS 2 - -0.2000 -0.4100 -0.1600 -0.5700 -0.2700 -0.1500 -0.0800 - -0.2200 -0.0900 -0.1200 -0.0400 -0.0200 0.0200 - -
Dividend per Share - - - - - - - - - - - - - - - - -
Announcement Date 8/12/20 4/12/22 5/11/22 8/11/22 8/11/22 11/9/22 5/12/23 8/29/23 8/29/23 11/8/23 4/24/24 5/22/24 - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 141 - - - - 269 235 71
Net Cash position 1 - 0.67 345 212 - - - -
Leverage (Debt/EBITDA) 1.149 x - - - - 2.766 x 1.236 x 0.2942 x
Free Cash Flow 1 10.9 -54.4 3.29 21.8 - -205 67 107
ROE (net income / shareholders' equity) 8.45% 1.04% 20.5% -13.7% - -5.64% 4.94% 5.47%
ROA (Net income/ Total Assets) 3.89% 0.47% 11.7% -7.82% - 0.8% 1.13% 2.06%
Assets 1 978.7 1,322 1,849 2,246 - -3,486 2,860 3,735
Book Value Per Share 2 3.180 4.420 7.810 6.720 - 6.030 6.360 6.490
Cash Flow per Share 2 0.2800 0.2900 0.7300 1.150 - 0.1900 0.7600 0.9400
Capex 1 31.3 99.1 119 181 - 160 116 127
Capex / Sales 7.02% 19.78% 19.25% 24.13% - 18.18% 11.2% 10.92%
Announcement Date 3/26/20 3/25/21 4/12/22 5/12/23 4/24/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Evotec SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
8.655 EUR
Average target price
20.79 EUR
Spread / Average Target
+140.21%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
EVOTEC SE Stock Evotec SE
-59.33% 1.66B
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.63B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
LONZA GROUP AG Stock Lonza Group AG
+37.52% 38.82B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. EVT Stock
  4. Financials Evotec SE